Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-40 in Chronic Lymphocytic Leukemia
NCT00283101Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Jul 2005
- Primary completion
- Oct 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of dacetuzumab in chronic lymphocytic leukemia (CLL), sponsored by Seagen Inc.. Started Jul 2005; status: completed.
02
Drugs
dacetuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00283101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00283101.